Cormedix | search
Click here to view Cormedix news from 60+ newspapers.
Bookmark or Share- CORMEDIX INC. REPORTS FOURTH QUARTER AND FULL YEAR 2023 ...Berkeley Heights, NJ – March 12, 2024 – CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced financial results for the fourth quarter and full year ended December 31, 2023 and ...
- Home - CorMedixCorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases.
- CorMedix Inc. (CRMD) Stock Price, News, Quote & History ...CYCCCyclacel Pharmaceuticals, Inc. 2.5228. +11.14%. Find the latest CorMedix Inc. (CRMD) stock quote, history, news and other vital information to help you with your stock trading and investing.
- Press Releases - CorMedixANNOUNCES CMS GRANTS TDAPA TO DEFENCATH. Read more. Apr 15, 2024. CORMEDIX INC. ANNOUNCES U.S. INPATIENT COMMERCIAL AVAILABILITY OF DEFENCATH® (TAUROLIDINE AND HEPARIN) Read more. Apr 11, 2024. CORMEDIX INC. ANNOUNCES ABSTRACTS AT UPCOMING SOCIETY FOR HEALTHCARE EPIDEMIOLOGY OF AMERICA CONFERENCE.
- CORMEDIX INC. ANNOUNCES FDA APPROVAL OF DEFENCATH® TO REDUCE ...Berkeley Heights, NJ – November 15, 2023 – CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced that the U.S. Food and Drug Administration (FDA) has approved DefenCath ...
More
